The patent on semaglutide expired in India on Friday bringing price discounts as deep as 70%-90%. The patent was sold in India since June 2025 under the originator brand. Semaglutide was originally patented as an active pharma ingredient for the management of Type 2 diabetes. Later it was found to be much more useful in controlling obesity. It works by regulating appetite and blood sugar in the human body. It belongs to a class of medicines known as GLP-1 receptor. As per analysts, more than 40 Indian drugmakers will launch over 50 cheaper variants.The global obesity market is projected to be around $100 billion by the end of the decade.
After the removal of patent, Noveltreat is expected to cost around Rs 900 to Rs 2000 for weekly treatment and Sematrinity will cost Rs 750 to Rs 1300, the company said. Natco Pharmaceuticals and Eris Lifesciences will provide the dose for Rs 1290 for the lowest dose per month. Zydus Lifesciences has launched its generic semaglutide injection in India at an average monthly cost of approximately ₹2,200. There are many more companies in the line. As per an estimate, 43 companies have either got regulatory approval for the drug or have generic variations in pipeline.
